Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about MANE, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| VDPHL01 | Androgenetic Alopecia | Phase 2/3 · NCT06724614 | Active not recruiting |
| VDPHL01 BID | Androgenetic Alopecia (AGA) | Phase 3 · NCT07146022 | Active not recruiting |
| VDPHL01 QD | Androgenetic Alopecia (AGA) | Phase 3 · NCT07146022 | Active not recruiting |
| VDMN-21 Patch High Dose | Verruca Vulgaris | Phase 2 · NCT05799157 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
MANE holds $798.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $18.7M/quarter from operations, an estimated runway of 128 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
Future Funding Requirements We believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements into 2030, based on our current operating plans.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MANE files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | Institution (13G, 5%+) | 4,172,121 | 9.89% | 2026-05-01 |
| FMR LLC | Institution (13G, 5%+) | 3,193,181 | 7.57% | 2026-06-30 |
| JPMORGAN CHASE & CO. | Institution (13G, 5%+) | 2,374,502 | 5.63% | 2026-09-30 |
| John W Childs Director · +51,525 options |
Insider | 1,907,889 | 4.52% | 2026-08-12 |
| Longitude Capital Partners V, LLC 10% owner |
Insider | 1,803,474 | 4.27% | 2026-11-11 |
| Patrick G Enright Director · +45,131 options Includes shares also reported by Longitude Capital Partners V, LLC, counted once |
Insider | 1,803,474 | 4.27% | 2026-11-11 |
| MONTANOVA CAPITAL, LLC Director |
Insider | 612,033 | 1.45% | 2026-08-19 |
| Vlad Coric Director · +51,525 options |
Insider | 449,337 | 1.06% | 2026-02-03 |
| Reid Alexander Waldman Chief Executive Officer, Director · +556,399 options |
Insider | 170,824 | 0.40% | 2026-08-17 |
| Seven Fleet Capital Management LP 10% owner |
Insider | 80,000 | 0.19% | 2026-05-01 |
| Timothy August Durso Chief Technical Officer · +213,352 options |
Insider | 78,142 | 0.19% | 2026-08-17 |
| David Hollander Chief R&D Officer · +19,300 options |
Insider | 9,650 | 0.02% | 2026-09-01 |
Share count 42,195,472 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MANE and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →